HelenHeslopMDDSc (Hon)

Hematologic Oncology

Dan L. Duncan Chair, Baylor College of Medicine Director, Center for Cell and Gene Therapy Deputy Director, Dan L Duncan Comprehensive Cancer Center Professor, Departments of Pediatrics and Medicine, and Center for Cell and Gene Therapy

Join to view full profile

Dr. Heslop is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Heslop's full profile

Already have an account?

Office
6701 Fannin St
Houston, TX 77030
Phone+1 832-822-4240

Fax+1 832-825-4247

Education & Training

University of Otago School of MedicineClass of 1980

Certifications & Licensure

TX State Medical License 2001 - 2026
TN State Medical License 1992 - 2004

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs) Start of enrollment: 2000 Jan 01
Completed
Phase 1
Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). Start of enrollment: 2001 Jan 01
Completed
Phase 1
Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL Start of enrollment: 1996 Jan 01
Completed
Phase 1
Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts Start of enrollment: 1993 May 01
Completed
Phase 1
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma Start of enrollment: 2003 Sep 01
Completed
Phase 1
Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant Start of enrollment: 2004 Apr 01
Completed
Phase 1
LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL) Start of enrollment: 2003 Oct 01
Terminated
Phase 1
Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) Start of enrollment: 2006 Apr 01
Active, not recruiting
Phase 1
T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC Start of enrollment: 2001 Aug 01
Completed
Phase 1
Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) Start of enrollment: 2008 Nov 01
Completed
Phase 1, Phase 2
Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma Start of enrollment: 2010 Feb 11
Active, not recruiting
Phase 1
Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes Start of enrollment: 2009 Nov 01
Completed
Phase 2
Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) Start of enrollment: 2011 Jan 01
Completed
Phase 1
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma Start of enrollment: 2011 May 10
Active, not recruiting
Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE Start of enrollment: 2013 Jan 14
Recruiting
Phase 1
ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus Start of enrollment: 2012 Sep 01
Completed
Phase 1, Phase 2
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma Start of enrollment: 2014 Sep 01
Terminated
Phase 2
Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant Start of enrollment: 2014 Jun 01
Completed
Not Applicable
TAA-Specific CTLS for Solid Tumors (TACTASOM) Start of enrollment: 2015 Apr 01
Completed
Phase 1
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) Start of enrollment: 2015 Feb 01
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant.
Ibrahim N Muhsen, Kristen E Shaver, Tao Wang, Mengfen Wu, Premal Lulla
Transplantation and Cellular Therapy. 2024-12-01
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers.
David Steffin, Nisha Ghatwai, Antonino Montalbano, Purva Rathi, Amy N Courtney
Nature. 2024-11-27
1 citations
Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors.
Anne Miller, Rachel Daum, Tao Wang, Mengfen Wu, Candise Tat
Cytotherapy. 2024-09-01

Journal Articles

EBV/LMP-specific T Cells Maintain Remissions of T and B Cell EBV Lymphomas After Allogeneic Bone Marrow Transplantation
Stephen Gottschalk, Rayne Rouce, Catherine M Bollard, Malcolm K Brenner, Helen E Heslop, Blood

Abstracts/Posters

Incorporation of Thiotepa in a Reduced Intensity Conditioning Regimen Leads to Improved Engraftment after Stem Cell Transplant for Patients with Hemophagocytic Lymphoh...
Helen E. Heslop, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Genomic Characterization of a Pediatric Cohort with Non-Malignant Lymphoproliferative Disorders
Helen E. Heslop, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell MalignanciesClinically Relevant Abstract
Helen E. Heslop, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Integration of Immunotherapy Into Treatment for Hematologic Malignancies
60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

Baylor College of Medicine Receives More Than $17 Million from CPRITAugust 21st, 2024
Tessa Therapeutics, Baylor College of Medicine Execute Agreement for Global Commercial Rights to ‘Off-the-Shelf’ CAR-T PlatformNovember 7th, 2022
Dr. Pavan Reddy Named Director of Dan L Duncan Comprehensive Cancer CenterJune 2nd, 2022
Join now to see all